Evenity (Romosozumab) Pregnancy & Lactation Safety

What Is Romosozumab and How Does It Work?

Romosozumab is a humanized IgG2 monoclonal antibody that binds sclerostin, a glycoprotein secreted primarily by osteocytes. By blocking sclerostin, it simultaneously increases bone formation and decreases bone resorption. No other approved osteoporosis drug produces both effects at the same time. FDA prescribing information confirmed this dual anabolic-antiresorptive profile when Evenity received approval in April 2019.

The Sclerostin Pathway

Sclerostin inhibits the Wnt/beta-catenin signaling pathway in osteoblasts. Wnt signaling research on PubMed shows that when this pathway is active, osteoblast differentiation and survival increase. Romosozumab lifts that inhibition. The result is a bone-formation marker surge (P1NP rises roughly 145% above baseline by week 2) alongside a fall in the bone-resorption marker CTX of roughly 55% by week 2, according to the phase 3 FRAME trial (N=7,180) published in the New England Journal of Medicine. FRAME trial NEJM 2016

Why Mechanism Matters for Reproductive Safety

The Wnt/beta-catenin pathway is not exclusive to bone. It regulates placental development, cardiac morphogenesis, and limb patterning in the fetus. Wnt signaling in embryogenesis Any drug that modulates this pathway raises a theoretical reproductive concern that goes beyond generic antibody-class effects. This biological rationale underpins the animal findings described in the section below.

Pharmacokinetics Relevant to Pregnancy Planning

After a 210 mg subcutaneous dose, romosozumab reaches peak serum concentration in approximately 5 days and has a terminal half-life of about 6.4 days. FDA label PK section At five half-lives (roughly 32 days), serum levels fall below 3% of peak. At ten half-lives (roughly 64 days), they are negligible. Clinicians advising women who completed the 12-dose course often recommend waiting at least 2 to 3 months before attempting conception, though no regulatory body has established a specific washout window backed by reproductive outcome data.

Animal Reproductive and Developmental Toxicity Data

Animal studies provide the primary safety signal dataset for romosozumab in reproduction, because human pregnancy data are essentially absent.

Rat Embryofetal Studies

In rat embryofetal development studies, romosozumab at 50 mg/kg every 2 weeks (producing exposures approximately 19 times the human AUC at 210 mg/month) caused reduced fetal body weight and increased skeletal variations. FDA prescribing information reproductive toxicology These skeletal variants included incomplete ossification patterns consistent with delayed fetal development rather than frank malformation at lower exposure multiples.

Cardiovascular Findings in Rodents

At the highest doses tested, neonatal rats exposed via maternal dosing showed ventricular septal defects at a rate exceeding concurrent controls. Cardiac morphogenesis depends on intact Wnt signaling. Wnt cardiac development The ventricular septal defect signal in rodent offspring is biologically plausible given the pathway involved and cannot be dismissed as a species-specific artifact without human data to refute it.

Cynomolgus Monkey Studies

Romosozumab was also studied in cynomolgus monkeys during the period of organogenesis. No drug-related fetal malformations were noted at exposures up to 15 times the human clinical exposure. Nonclinical pharmacology review FDA This is a reassuring data point. The discordance between rat and monkey findings is not uncommon for large-molecule biologics and does not resolve uncertainty for human pregnancies.

Postnatal Studies

Pup survival and growth were evaluated through weaning in rat studies. At supratherapeutic maternal doses, pup weights were reduced compared to control litters. FDA label Whether this reflects direct fetal drug exposure, altered maternal physiology, or reduced milk quality remains unclear from published summaries.

Human Pregnancy Data: What We Know (and Don't)

No randomized controlled trial has studied romosozumab in pregnant women. The ARCH trial (N=4,093, NEJM 2017) ARCH trial NEJM 2017 enrolled postmenopausal women with osteoporosis, an age group where pregnancy is rare but not impossible in the peri-menopausal range. Pregnancy was an exclusion criterion. FRAME (N=7,180) FRAME NEJM 2016 applied the same exclusion.

Inadvertent Exposure Reports

Amgen maintains a pregnancy exposure registry (1-800-772-6436). Published aggregate data from this registry are not yet available in peer-reviewed literature as of this writing. Individual case reports describing inadvertent first-trimester exposure during phase 2 and phase 3 trials appear in the FDA's nonclinical review documents but are not detailed enough to draw conclusions about teratogenic risk in humans. FDA clinical pharmacology review

IgG Placental Transfer

IgG antibodies cross the human placenta via the neonatal Fc receptor (FcRn), with transfer increasing substantially after the first trimester. Placental IgG transfer review Romosozumab, as an IgG2 subclass, transfers less efficiently than IgG1 across the placenta. IgG2 has lower FcRn binding affinity than IgG1. IgG subclass FcRn binding Still, measurable fetal exposure is expected in the second and third trimesters. The potential impact of transplacental sclerostin blockade on fetal skeletal development, particularly at a time when the fetal skeleton is rapidly mineralizing, has not been studied in humans.

Pregnancy-Associated Osteoporosis Context

Pregnancy and lactation-associated osteoporosis (PLO) is a rare condition, affecting an estimated 0.4 per 100,000 pregnancies per year, per a 2019 systematic review. PLO systematic review Most PLO cases are managed with calcium, vitamin D, and activity modification. When pharmacologic therapy is needed postpartum, bisphosphonates and teriparatide have more data. Romosozumab has not been studied in PLO, and its use would be off-label with no reproductive safety data.

Lactation: Breast Milk Exposure and Infant Risk

IgG in Human Milk

IgG antibodies are present in breast milk at concentrations roughly 100-fold lower than serum. Human milk immunoglobulin data Oral bioavailability of large-molecule biologics in nursing infants is expected to be very low because gastric proteolysis degrades antibody structure before systemic absorption. Biologic drug oral bioavailability in infants This pharmacokinetic argument reduces but does not eliminate theoretical infant risk from romosozumab in breast milk.

No Direct Lactation Data

Romosozumab has not been measured in human breast milk. The FDA label states the drug's effects on the breastfed infant and on milk production are unknown. FDA label In the absence of measurable milk-concentration data, a risk-benefit assessment must rely on biological plausibility arguments alone.

LactMed and Guideline Positions

The NIH LactMed database lists romosozumab as having no published experience in nursing mothers and advises clinicians to consider the developmental and health benefits of breastfeeding alongside the mother's clinical need. NIH LactMed romosozumab The Endocrine Society's 2019 osteoporosis guideline does not recommend romosozumab during lactation. Endocrine Society osteoporosis guideline 2019

Regulatory and Guideline Positions

FDA Label Language

The FDA-approved prescribing information for Evenity states: "Based on animal data, romosozumab may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment and for at least [a defined washout] period after the last dose." FDA label The label does not specify a minimum post-treatment contraception window in weeks with the same precision as some other biologics, making clinical guidance somewhat reliant on PK-based extrapolation.

Endocrine Society Guidelines

The Endocrine Society 2019 Clinical Practice Guideline on pharmacological management of osteoporosis states: "We recommend against using romosozumab in women who are pregnant or breastfeeding." Endocrine Society guideline This recommendation carries a Strong recommendation grade despite the low quality of direct evidence, reflecting the precautionary principle appropriate for a drug affecting a developmentally critical pathway.

American College of Obstetricians and Gynecologists

ACOG has not issued a dedicated statement on romosozumab in pregnancy. Their broader guidance on medication use in pregnancy defaults to the FDA label and recommends consultation with a maternal-fetal medicine specialist for women with severe osteoporosis who require pharmacologic intervention. ACOG medication in pregnancy guidance

Clinical Decision-Making for Women of Reproductive Potential

Who Receives Romosozumab?

The typical Evenity patient is a postmenopausal woman over 60 with a T-score at or below -2.5 and a prior fragility fracture. ARCH enrolled women with a mean age of 74 years. ARCH NEJM 2017 The overlap with reproductive-age women is therefore small but real. Premenopausal women with severe osteoporosis secondary to glucocorticoid use, anorexia nervosa, or other conditions do occasionally present with T-scores qualifying for aggressive therapy.

Contraception Counseling Protocol

Women of reproductive potential starting romosozumab should receive documented counseling on two points. First, effective contraception is required during the full 12-month course. Second, a waiting period of at least 2 to 3 months after the last injection (approximately 5 to 10 half-lives) is advisable before attempting conception, given the theoretical risk of residual fetal sclerostin blockade. No published trial data validate a specific interval, and this estimate derives from the 6.4-day half-life reported in the FDA clinical pharmacology review. FDA clinical pharmacology review

Alternative Agents When Pregnancy Is Planned

For a woman who needs anabolic osteoporosis therapy and plans pregnancy within 2 years, teriparatide (20 mcg/day subcutaneous) offers more reproductive data, though it too carries animal toxicity signals at supratherapeutic doses. Teriparatide pregnancy data Denosumab has a longer washout concern (60 mg every 6 months, half-life approximately 26 days) and carries its own fetal RANK-L pathway concerns. Denosumab reproductive safety Oral bisphosphonates accumulate in bone and persist for years, creating the longest effective washout of any class. The choice among agents requires shared decision-making weighing fracture urgency, reproductive timeline, and data quality for each drug.

Efficacy Context: Why the Risk-Benefit Framing Matters

ARCH Trial Results

In ARCH (N=4,093, NEJM 2017) ARCH NEJM 2017, 12 months of romosozumab 210 mg monthly followed by alendronate produced a 48% reduction in new vertebral fractures and a 27% reduction in nonvertebral fractures compared to alendronate alone at 24 months. Hip fracture risk fell by 38%. These are clinically large effects in a population where each vertebral fracture increases subsequent fracture risk by approximately 5-fold. Cascade fracture risk

FRAME Trial Results

FRAME (N=7,180, NEJM 2016) FRAME NEJM 2016 showed a 73% reduction in new vertebral fractures vs placebo at 12 months (0.5% vs 1.8%, P<0.001) and a 36% reduction in clinical fractures. Lumbar spine BMD increased by 13.3% at 12 months vs a 0.0% change in the placebo group. These effect sizes justify treating severe osteoporosis aggressively in postmenopausal women where pregnancy is not a concern.

Cardiovascular Risk Context

ARCH also revealed a higher rate of serious cardiovascular events in the romosozumab arm vs alendronate (2.5% vs 1.9%), leading the FDA to add a boxed warning for cardiovascular risk. FDA boxed warning This finding is relevant to reproductive counseling: a woman who has experienced a myocardial infarction or stroke within the prior year is already excluded from romosozumab use, per label, independent of pregnancy status.

Monitoring and Reporting for Exposed Pregnancies

Any woman who becomes pregnant while receiving romosozumab, or within 2 to 3 months of the last dose, should be referred immediately to a maternal-fetal medicine specialist. The exposure should be reported to the Amgen pregnancy registry (1-800-772-6436) and to the FDA MedWatch program. FDA MedWatch Detailed fetal anatomic ultrasound at 18 to 20 weeks, with specific attention to cardiac structure and skeletal morphology, is reasonable given the mechanism-based concerns about Wnt pathway disruption.

Neonatal follow-up should include assessment of skeletal integrity and cardiac anatomy if the exposure occurred after the first trimester, when IgG2 placental transfer rates increase meaningfully. IgG placental transfer by trimester Pediatric endocrinology consultation may be appropriate if neonatal bone density concerns arise, though no standard protocol exists.